In this guest blog post, Jennifer Graff, PharmD , discusses incorporating value in coverage decisions and how this applies to AMCP's efforts in addressing value and access.
During AMCP 2022 in March, Dr. Kali Cyrus lead a workshop titled: A Primer on Bias from Discovery to Implementing Strategies to Address. AMCP CEO, Susan Cantrell explores the highlights from this workshop and how managed care professionals may be able to implement Dr. Cyrus' strategies in their day-to-day.
In 2016, AMCP made pre-approval information exchange (PIE) a legislative priority recognizing its vital importance to patients. On June 8, 2022, the U.S. House of Representatives passed the PIE Act of 2022. Learn more about PIE as a legislative priority for AMCP.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
Today, the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) announced that it has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review.
